title: Development of a fluorescence-based assay to screen antiviral drugs against Kaposi's sarcoma associated herpesvirus.
abstract: Tumors associated with Kaposi's sarcoma-associated herpesvirus infection include Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Virtually all of the tumor cells in these cancers are latently infected and dependent on the virus for survival. Latent viral proteins maintain the viral genome and are required for tumorigenesis. Current prevention and treatment strategies are limited because they fail to specifically target the latent form of the virus, which can persist for the lifetime of the host. Thus, targeting latent viral proteins may prove to be an important therapeutic modality for existing tumors as well as in tumor prevention by reducing latent virus load. Here, we describe a novel fluorescence-based screening assay to monitor the maintenance of the Kaposi's sarcoma-associated herpesvirus genome in B lymphocyte cell lines and to identify compounds that induce its loss, resulting in tumor cell death.
authors: Department of Microbiology and Immunology, Lineberger Cancer Center, University of North Carolina at Chapel Hill, North Carolina, NC 27599, USA.
authors: Tamara K
authors: TK
authors: Nun
authors: David J
authors: DJ
authors: Kroll
authors: Nicholas H
authors: NH
authors: Oberlies
authors: Djaja D
authors: DD
authors: Soejarto
authors: Ryan J
authors: RJ
authors: Case
authors: Pius
authors: P
authors: Piskaut
authors: Teatulohi
authors: T
authors: Matainaho
authors: Chelsey
authors: C
authors: Hilscher
authors: Ling
authors: L
authors: Wang
authors: Dirk P
authors: DP
authors: Dittmer
authors: Shou-Jian
authors: SJ
authors: Gao
authors: Blossom
authors: B
authors: Damania
mesh_terms: D000956:Antigens, Viral / Q000378:metabolism; D000998:Antiviral Agents / Q000494:pharmacology*; D001681:Biological Assay / Q000379:methods; D016923:Cell Death / Q000187:drug effects; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D005453:Fluorescence; D005455:Fluorescent Antibody Technique; D019288:Herpesvirus 8, Human / Q000187:drug effects*; D006801:Humans; D009687:Nuclear Proteins / Q000378:metabolism; D010936:Plant Extracts / Q000494:pharmacology; D015203:Reproducibility of Results; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000956:Antigens, Viral; D000998:Antiviral Agents; D009687:Nuclear Proteins; D010936:Plant Extracts; C109540:latency-associated nuclear antigen
references: J Virol. 1997 Jan;71(1):715-9
references: 8985403
references: Virology. 1999 Nov 25;264(2):254-64
references: 10562490
references: Curr Opin Oncol. 2005 Sep;17(5):447-55
references: 16093794
references: Curr Oncol Rep. 2005 Sep;7(5):349-56
references: 16091195
references: J Nat Prod. 2003 Jul;66(7):1022-37
references: 12880330
references: Nature. 1999 Dec 23-30;402(6764):889-94
references: 10622254
references: J Nat Prod. 1998 Aug;61(8):1053-71
references: 9722499
references: Science. 2006 Feb 10;311(5762):856-61
references: 16469929
references: J Virol. 2005 Nov;79(22):14383-91
references: 16254372
references: Nat Rev Drug Discov. 2005 Mar;4(3):206-20
references: 15729362
references: Blood. 1996 Jul 15;88(2):645-56
references: 8695812
references: N Engl J Med. 1995 May 4;332(18):1186-91
references: 7700311
references: J Virol. 2000 Oct;74(20):9637-45
references: 11000236
references: J Virol. 2002 Jun;76(12):6213-23
references: 12021355
references: J Clin Invest. 2005 Mar;115(3):642-52
references: 15765147
references: Phytomedicine. 1996 Nov;3(3):281-5
references: 23195084
references: Int J Cancer. 2007 Jan 15;120(2):321-8
references: 17066452
references: J Virol. 2002 Jun;76(12):6185-96
references: 12021352
references: J Virol. 2003 Jul;77(14):8019-30
references: 12829841
references: Nat Med. 1996 Mar;2(3):342-6
references: 8612236
references: J Cell Biochem Suppl. 2001;Suppl 36:117-28
references: 11455577
references: Blood. 1995 Aug 15;86(4):1276-80
references: 7632932
references: J Virol. 1998 Feb;72(2):1005-12
references: 9444993
references: Antimicrob Agents Chemother. 2001 Dec;45(12):3654-6
references: 11709363
references: J Clin Microbiol. 2000 Apr;38(4):1404-8
references: 10747115
references: J Clin Invest. 2004 Jan;113(1):124-36
references: 14702116
references: Am J Pathol. 2000 Mar;156(3):743-9
references: 10702388
references: J Natl Cancer Inst. 2002 Aug 21;94(16):1204-10
references: 12189223
references: J Gen Virol. 2000 Nov;81(Pt 11):2645-52
references: 11038375
references: Am J Med. 1979 Nov;67(5):759-65
references: 159624
references: J Biol Chem. 2002 Jul 26;277(30):27401-11
references: 12015325
references: J Virol. 2002 Jan;76(2):802-16
references: 11752170
references: N Engl J Med. 2000 Apr 6;342(14):1027-38
references: 10749966
references: Leuk Lymphoma. 2002 Mar;43(3):631-4
references: 12002770
references: Science. 1999 Apr 23;284(5414):641-4
references: 10213686
references: J Nat Prod. 2004 Feb;67(2):129-35
references: 14987046
references: J Virol. 1999 Dec;73(12):9789-95
references: 10559289
references: Hematol Oncol Clin North Am. 2003 Jun;17(3):673-96, v
references: 12852650
references: Blood. 2005 Dec 1;106(12):3797-802
references: 16091453
references: J Am Chem Soc. 1971 May 5;93(9):2325-7
references: 5553076
references: J Nat Prod. 2004 Dec;67(12):2141-53
references: 15620274
references: Protein Eng. 1999 Dec;12(12):1035-40
references: 10611396
references: J Nat Prod. 1997 Jan;60(1):52-60
references: 9014353
references: Nat Med. 2000 Oct;6(10):1121-7
references: 11017143
references: J Virol. 2005 Sep;79(17):10952-67
references: 16103147